Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial

JAMA

Volumn 279, Issue 15, 1998, Pages 1181-1186

  Knorr, Barbara ^a   Matz, Jonathan ^b   Bernstein, Jonathan A ^b   Nguyen, Ha ^a   Seidenberg, Beth C ^a   Reiss, Theodore F ^a   Becker, Allan ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Atl Asthma and Allergy Center Inc ^*  (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CROMOGLYCATE DISODIUM; LEUKOTRIENE; MONTELUKAST;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BLOOD VESSEL PERMEABILITY; BRONCHOSPASM; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FORCED EXPIRATORY VOLUME; MUCUS SECRETION; PRIORITY JOURNAL; SPIROMETRY;

EID: 0032522735     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.15.1181     Document Type: Article

References (26)

1. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma: NHLBI Workshop Report. Bethesda, Md: National Heart, Lung, and Blood Institute, National Institutes of Health; 1995.
2. Weitzman N, Gortmaker SL, Sobol AM, Perrin JM. Recent trends in the prevalence and severity of childhood asthma. JAMA. 1992;268:2673-2677.
3. Gergen PJ, Weiss KB. Changing patterns of asthma hospitalization among children: 1979 to 1987. JAMA. 1990;264:1688-1692.
4. Dahlén SE, Hedqvist P, Hammarström S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 1980;288:484-486.
5. 4 in humans. Am Rev Respir Dis. 1985;131:368-372.
6. 4 and to methacholine in patients with asthma and normal controls. N Engl J Med. 1986;315:480-484.
7. Israel E, Cohn J, Dubé L, Drazen JM, for the Zileuton Clinical Trial Group. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA. 1996;275:931-936.
8. Spector SL, Smith LJ, Glass M, and the Accolate Asthma Trialist Group. Effects of 6 weeks of therapy with oral doses of ICI 204, 219, a leukotriene D4-receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med. 1994;150:618-623.
9. 4 receptor antagonist, improves the signs and symptoms of asthma with a dose as low as 10 mg once daily [abstract]. Am J Respir Crit Care Med. 1995;151:A378.
10. 4 receptor antagonist, exhibits a dose related improvement in the once daily treatment of patients with chronic asthma [abstract]. Eur Respir J. 1995;19:289s.
11. 1 receptor antagonist, improves the signs and symptoms of asthma over a 3 month treatment period [abstract], Eur Respir J. 1996;9:273s.
12. Clark TJH, Hetzel MR. Diurnal variation of asthma. Br J Dis Chest. 1977;71:87-92.
13. Crapo RD, Hankinson JL, Irvin C. Standardization of spirometry. Am J Respir Crit Care Med. 1995;152:1107-1136.
14. Santanello NC, Barber BL, Knorr BA. Validation of a pediatric asthma diary [abstract]. J Allergy Clin Immunol. 1996;97:257.
15. Juniper EF, Guyatt GH, Feeny P, Ferrie PJ, Griffith LE, Townsend M. Measuring the quality of life in children with asthma. Qual Life Res. 1996;5:35-46.
16. Tanner JM. Growth at Adolescence. Springfield, Ill: Charles C Thomas Publishers Inc; 1956.
17. Shapiro GG, Sharpe M, DeRouen TA, et al. Cromolyn versus triamcinolone acetonide for youngsters with moderate asthma. J Allergy Clin Immunol. 1991;88:742-748.
18. Simons FER. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med. 1997;337:1659-1665.
19. Van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis. 1992;146:547-554.
20. Kraemer R, Modelska K, Casaulta C, Schöni MH. Comparison of different inhalation schedules to control childhood asthma. Agents Actions Suppl. 1993;40:211-221.
21. Mac Kenzie CA, Weinberg EG, Tabachnik E, Taylor M, Havnen J, Crescenzi K. A placebo controlled trial of fluticasone propionate in asthmatic children. Eur J Pediatr. 1993;152:856-860.
22. Tinkelman DG, Reed CE, Nelson HS, et al. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics. 1993;92:64-77.
23. Shapiro GG, König P. Cromolyn sodium: a review. Pharmacotherapy. 1985;5:156-170.
24. Leff JA, Israel E, Noonan MJ, et al. Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability [abstract]. Am J Respir Crit Care Med. 1997;155:A976.
25. Jeffery PK, Wardlaw AJ,Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis. 1989;140:1745-1753.
26. Wempe JB, Tammeling EP, Koeter GH, Hakansson L, Venge P, Postma DS. Blood eosinophil numbers and activity during 24 hours: effects of treatment with budesonide and bambuterol. J Allergy Clin Immunol. 1992;90:757-765.